Biotest AG (Biotest), a subsidiary of Grifols SA develops, manufactures and distributes biological medicines obtained from human blood plasma or manufactured through biotechnology methods. Its medicines are used in the areas of clinical immunology, haematology and intensive care medicine. The company operates its business through three operating segments, namely, Therapy, Plasma & Services, and Other Segments.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biotest's R&D focuses on the development of new products in therapeutic areas including clinical immunology, haematology and intensive care medicine. It also focuses on developing its approved products for new indications. Biotest is actively involved in the continuous improvement and ongoing clinical development of its licensed products in the field of haematology. Additionally, the company is focused on expanding the range of clotting factors, which is of particular importance in the treatment of haematological conditions. Biotest has established itself as a leading authority in the field of immunology with its extensive proficiency in therapy involving polyvalent immunoglobulins (IVIg) for primary immune deficiencies and autoimmune diseases. The company is actively engaged in the development of medications targeting chronic progressive immune system disorders. One notable advancement is IgG Next Generation, a newly developed IVIg treatment designed specifically for addressing immunodeficiency and autoimmune diseases. Biotest is actively involved in the advancement of intensive care medicine, specifically through the development of trimodulin, a polyvalent antibody preparation. Trimodulin is uniquely formulated to include significant quantities of IgM and IgA antibodies alongside IgG, making it a promising treatment option for patients suffering from severe community-acquired pneumonia (sCAP) as well as those with severe COVID-19. The company’s pipeline products include CMV Hyperimmunglobulin in Phase III clinical trials indicated for the treatment of women who are infected with Cytomegalovirus (CMV); BT524 (fibrinogen) in Phase III indicated for the treatment of congenital fibrinogen deficiency and acquired fibrinogen deficiency. Biotest is investigating BT588 (Trimodulin) in Phase III clinical trials for the treatment of severe community-acquired pneumonia and severe COVID-19; and haemophilia A therapeutic (HAT) in pre-clinical studies for the treatment of haemophilia A. Biotest operates plasma collection centers in Germany, Czech Republic, and Hungary. It also seeks to work in partnership with other companies to develop its product candidates. In FY2022, the company incurred expenses of EUR49.9 million on its R&D, which as a percentage of sales, stood at 9.7%.